Recent Updates
Recently added Catalysts

Ultragenyx Pharmaceutical Inc.

RAREFDA catalysts, PDUFA dates & pipeline intelligence
$16.7
▲ +0.8 · +5.03%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full RARE financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $12.7352W HIGH $39.89
Volume
5.59 M
Value Traded
92.35 M
Short % Float
25.33%
Days to Cover
8.3
0%Week
+10.82%1 Month
-36.36%3 Month
-28.54%6 Month
-79.38%5 Year
-48.93%All Time

Cash Data

Unlock RARE cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.70 B
EPS (TTM)
-5.14
P/E Ratio
-
Ent. Value
1.30 B
Total Shares
101.92 M
Float Shares
93.25 M
Insiders
8.51%
Institutions
107.07%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout
DTX301 (avalotcagene ontaparvovec)
Ornithine transcarbamylase (OTC) deficiency
Phase 3Gene TherapiesRare Disease
Unlock every RARE catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RARE Catalyst Timeline

Dated clinical, regulatory and corporate events for Ultragenyx Pharmaceutical Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Ultragenyx Pharmaceutical Inc.

856Total events
15Upcoming
245Tier-1 (high impact)
2012 to 2028Coverage

Upcoming catalysts 2

T2Quarterly Update
Subscribe to view catalyst details
T1Topline Readout
Subscribe to view catalyst details
DTX301

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲FDA Filing AcceptedUX111ApprovedRegulatory Filing
MHRA accepted MAA for rebisufligene etisparvovec (UX111) for MPS IIIA
mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type Asource ↗
▲PRV SoldDesignation
Ultragenyx enters definitive agreement to sell Rare Pediatric Disease PRV for $203 million
mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A)source ↗
▲PRV SoldDesignation
Ultragenyx agrees to sell Rare Pediatric Disease PRV for $210 million
glycogen storage disease type Ia (GSDIa)source ↗
▲PRV SoldDesignation
Previously announced GENGLYCOS PRV transaction
▲PRV SoldGENGLYCOSApprovedDesignation
Sale of GENGLYCOS PRV closed for $210 million
glycogen storage disease type Ia (GSDIa)source ↗
▲PRV SoldFAYUVIApprovedDesignation
Definitive agreement to sell FAYUVI PRV for $203 million
Sanfilippo syndrome type A (MPS IIIA)source ↗
●EU MAA SubmissionUX111ApprovedEx-US Regulatory
Start of EMA Marketing Authorisation Application review for UX111
mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type Asource ↗
▲FDA ApprovalFAYUVIApprovedFDA Decision
FDA grants standard full approval of FAYUVI for MPS IIIA
Sanfilippo syndrome Type A (MPS IIIA)source ↗
▲PRV GrantedFAYUVIApprovedDesignation
Ultragenyx receives Priority Review Voucher upon FAYUVI approval
Sanfilippo syndrome Type A (MPS IIIA)source ↗
Unlock the full RARE catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RARE actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-03UX701 (rivunatpagene miziparvovec) Phase 1/2 data readout Phase 1/2
Unlock 14 more RARE historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 27%
Micro Cap
(rank 196 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
Crysvita
Dojolvi
Evkeeza
Mepsevii
Showing 27 of 34 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
setrusumab BiologicsNCT06636071Osteogenesis ImperfectaPhase 3 ACTIVE NOT_RECRUITING 258Jan 1, 2028
UX016 Small MoleculesNCT07511556GNE MyopathyPhase 1/2 RECRUITING 24Dec 1, 2028
UX111 Gene TherapiesMarketedNCT02716246MPS IIIAApproved RECRUITING 36Mar 1, 2029
DTX301 Gene TherapiesNCT05345171OTC DeficiencyPhase 3 ACTIVE NOT_RECRUITING 37Mar 1, 2031
Triheptanoin Small MoleculesMarketedNCT05933200Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Approved ACTIVE NOT_RECRUITING 69Aug 1, 2027
UX701 Gene TherapiesNCT04884815Wilson DiseasePhase 1/2 ACTIVE NOT_RECRUITING 82Mar 1, 2034
GTX-102 RNA-Based TherapiesCompletedNCT04259281Angelman SyndromePhase 1/2 COMPLETED 74Jan 8, 2025
setrusumab BiologicsCompletedNCT03118570Osteogenesis Imperfecta, Type IPhase 2 COMPLETED 112Nov 12, 2020
BPS804 BiologicsCompletedNCT01417091Osteogenesis ImperfectaPhase 2 COMPLETED 10Dec 1, 2012
DTX401 Gene TherapiesMarketedNCT05139316Glycogen Storage Disease Type IAApproved COMPLETED 52Feb 20, 2026
Burosumab BiologicsMarketedNCT03581591HypophosphatemiaApproved COMPLETED 1Dec 6, 2019
Evinacumab BiologicsMarketedNCT05611528Homozygous Familial HypercholesterolemiaApproved COMPLETED 10Mar 18, 2025
UX003 Small MoleculesMarketedNCT02230566MPS 7Approved COMPLETED 12May 1, 2016
UX003 Small MoleculesMarketedNCT02418455Sly SyndromeApproved COMPLETED 20Mar 26, 2019
scAAV8OTC Gene TherapiesCompletedNCT02991144Ornithine Transcarbamylase (OTC) DeficiencyPhase 1/2 COMPLETED 16Dec 16, 2021
DTX401 Gene TherapiesNot countedNCT03517085GSD1Phase 1/2 COMPLETED 12Nov 2, 2021
UX003 Small MoleculesMarketedNCT01856218Mucopolysaccharidosis Type 7Approved COMPLETED 3Jul 1, 2016
UX007 Small MoleculesNot countedNCT01993186Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Phase 2 COMPLETED 36Sep 20, 2017
UX007 Small MoleculesMarketedNCT01886378Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Approved COMPLETED 29Aug 25, 2016
UX007 Small MoleculesNot countedNCT02214160Carnitine Palmitoyltransferase (CPT I or CPT II) DeficiencyPhase 2 COMPLETED 94Dec 3, 2020
Triheptanoin Small MoleculesNot countedNCT00947960Adult Polyglucosan Body DiseasePhase 2 COMPLETED 23Jul 1, 2015
Triheptanoin Small MoleculesNot countedNCT02432768Glycogen Storage Disease Type VPhase 2 COMPLETED 22Feb 1, 2019
Triheptanoin Small MoleculesNot countedNCT03642860Tarui DiseasePhase 2 COMPLETED 3Aug 28, 2019
Triheptanoin Small MoleculesNot countedNCT02036853Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)Phase 2 COMPLETED 20Jun 30, 2019
Triheptanoin Small MoleculesNot countedNCT03506425ALSPhase 1/2 COMPLETED 15Mar 28, 2019
Unlock the RARE pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RARE program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Osteogenesis ImperfectaPhase 32026-03-30statistically significant reduction in annualized fracture rateRead MoreRARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmRead More
Scroll for more · summaries link to the source press release
Unlock every RARE trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RARE insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Horn HowardOfficer (Chief Financial Officer)Sell -7,066 89,229 held$15.27 10/15/2026
Unlock the full RARE insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RTW INVESTMENTS, LP 1.3 % (-40.9 %) 128.20 M 8.53 M 9.39% ( 732.50 K)
Unlock every fund holding RARE
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RARE
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see RARE ownership
Insider and institutional ownership, quarter by quarter.

RARE Short Interest

Shares sold short, counted twice a month.

25.33%
Short % of Float
of tradable shares sold short
23.6M
Shares Sold Short
+17.3% vs prior count
8.3 High
Days to Cover
trading days of normal volume to buy every short share back
2.9M
Avg Daily Volume
the average used for days to cover
Unlock RARE short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock RARE option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RARE option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RARE options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RARE ranks across every disease it competes in

Competitive Position is a premium feature
See how RARE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RARE News

RARE
Nov 11, 2026
RAREConferences/Events

Ultragenyx to Participate at Investor Conferences in London

Ultragenyx Pharmaceutical Inc. will participate in two investor conferences in November 2026. The UBS Global Biopharma Conference is scheduled for November 16, followed by the Jefferies Global Healthcare Conference on November 17. The leadership team will engage in fireside chats and one-on-one meetings with investors.

Read more →
RARE
Nov 6, 2026
RAREFDA Updates

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Ultragenyx announced that the UK MHRA accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111) on October 28, 2026. The therapy targets Sanfilippo syndrome Type A, an ultra-rare genetic disorder. This acceptance initiates a formal scientific review of the investigational gene therapy. The company is aligning NICE evaluation with the MHRA review for potential NHS access.

Read more →
RARE
Nov 3, 2026
RAREGeneral

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

Ultragenyx reported third quarter 2026 revenues of $173 million, driven by CRYSVITA and DOJOLVI sales. The company announced significant expense reductions and reaffirmed its guidance for profitability in 2027. Two BLAs for gene therapies received FDA approval, with Priority Review Vouchers expected to generate substantial revenue. However, a net loss of $118 million was reported for the quarter.

Read more →
RARE
Oct 27, 2026
RAREConferences/Events

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. will host a conference call on November 3, 2026, at 5:00 p.m. ET to discuss its financial results for Q3 2026. The call will be accessible via the company's website, with a replay available for three months. The company focuses on developing therapies for rare genetic diseases.

Read more →
RARE
Oct 14, 2026
RAREGeneral

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Ultragenyx Pharmaceutical Inc. has announced a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million. This sale follows a recent PRV transaction and aims to provide non-dilutive funding to support the company's innovative treatments for rare diseases. The transaction is subject to customary closing conditions, including regulatory reviews.

Read more →
RARE
Oct 7, 2026
RAREGeneral

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Ultragenyx Pharmaceutical Inc. has announced a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. This voucher was awarded following the FDA approval of GENGLYCOS, a treatment for glycogen storage disease type Ia. The funds will aid in advancing therapies for rare diseases, although the transaction is subject to customary closing conditions.

Read more →
RARE
Oct 2, 2026
RAREFDA Updates

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

Ultragenyx announced the validation of its Marketing Authorisation Application for rebisufligene etisparvovec, an investigational gene therapy for MPS IIIA. This validation allows the EMA to begin a formal review, although it does not guarantee approval. The therapy aims to address a significant unmet medical need in a rare disease community.

Read more →
RARE
Sep 17, 2026
RAREFDA Updates

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc. announced that the FDA has granted full approval for FAYUVI™, the first-ever treatment for Sanfilippo syndrome Type A. This gene therapy aims to halt the disease's progression and will be available to Qualified Treatment Centers within 30-60 days. The approval is a significant milestone for the affected community, offering hope to families facing this devastating condition.

Read more →
RARE
Sep 2, 2026
RAREPhases
▼ -44%on this news

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Ultragenyx announced that its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet its primary and secondary endpoints. The results have led to disappointment from the company and the patient community. The company will evaluate the program's future and implement expense reductions while focusing on its commercial business.

Read more →
RARE
Sep 1, 2026
RAREPhases

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

Ultragenyx announced that GENGLYCOS reduced daily cornstarch intake by 61% in a 96-week trial for GSDIa. The therapy maintained glycemic control while allowing 33% to 42% of patients to eliminate nighttime dosing. These results were published in The Journal of Inherited Metabolic Disease. The drug received FDA approval for patients aged eight and older.

Read more →
RARE
Aug 25, 2026
RAREGeneral

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. has granted 45,984 restricted stock units to 23 newly hired non-executive officers as part of its Employment Inducement Plan. This grant, approved by the compensation committee, aims to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.

Read more →
RARE
Aug 19, 2026
RAREFDA Updates

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

The U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS, a gene therapy for glycogen storage disease type Ia. This marks Ultragenyx’s first gene therapy approval and fifth overall regulatory clearance. The decision follows Phase 3 data showing reduced cornstarch requirements in 46 participants. Ultragenyx will receive a Priority Review Voucher as part of the approval process.

Read more →
RARE
Aug 4, 2026
RAREGeneral

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx reported second quarter total revenue of $214 million, driven by $156 million from Crysvita and $27 million from Dojolvi. The company reaffirmed its full year 2026 revenue guidance of $730 million to $760 million. It also maintained its outlook for combined research and development plus selling, general, and administrative expenses to remain flat to slightly down compared to 2025 levels.

Read more →
RARE
Jul 28, 2026
RAREConferences/Events

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. will host a conference call on August 4, 2026, at 5:00 p.m. ET to discuss its financial results for Q2 2026. The call will provide a corporate update and will be available for replay on the company's website for three months. Ultragenyx is dedicated to developing therapies for rare genetic diseases.

Read more →
RARE
Jul 8, 2026
RAREGeneral

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report, highlighting its commitment to rare disease patients and innovation. The report details advancements in five investigational therapies and ongoing support for patients lacking access to approved treatments. Key achievements include significant investments in R&D and participation in global advocacy events, reflecting the company's dedication to improving patient outcomes.

Read more →
RARE
Jun 3, 2026
RAREConferences/Events

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Ultragenyx Pharmaceutical Inc. will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. CEO Emil Kakkis will engage in a fireside chat, which will be available via live and archived webcast. The company focuses on developing therapies for rare genetic diseases and has a strong commitment to efficient drug development.

Read more →
RARE
May 6, 2026
RAREConferences/Events

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

Ultragenyx Pharmaceutical Inc. will participate in Bank of America's 2026 Healthcare Conference on May 12, 2026. CFO Howard Horn and Chief of Staff Joshua Higa will lead a fireside chat, which will be accessible via webcast. The company focuses on developing therapies for rare genetic diseases and aims to address high unmet medical needs.

Read more →

About Ultragenyx Pharmaceutical Inc.

Novato, CA 1,371 employees ultragenyx.com
Headquarters60 LEVERONI COURT, NOVATO, CA, 94949
BIOPHARMAWATCH ELITE
Trade the next RARE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime